IP Library › Granted Patent US 9,982,007
Granted Patent B2
US 9,982,007 · App. 15/333,691 · Granted May 29, 2018

Cocrystals of progesterone

Inventors: Ekaterina Albert (West Lafayette, IN); Patricia Andres (West Lafayette, IN); Melanie Janelle Bevill (West Lafayette, IN); Jared Smit (Lafayette, IN); Jennifer Nelson (Kokomo, IN)
Assignee: AMRI SSCI, LLC
C07J7/002C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,982,007
App. No.
15/333,691
Granted
May 29, 2018
Kind
B2
Abstract

The present invention relates to a cocrystal of progesterone and a coformer selected from the group consisting of vanillic acid, benzoic acid, salicylic acid, cinnamic acid, and vanillin. The present invention also relates to a pharmaceutical composition comprising a cocrystal of the present invention and at least one pharmaceutically acceptable carrier. The present invention further relates to a method of supplementing progesterone in women. This method involves administering to a female subject in need thereof a pharmaceutical composition of the present invention.

Claims (21)

1. A cocrystal of progesterone and a coformer selected from the group consisting of vanillic acid, benzoic acid, salicylic acid, cinnamic acid, and vanillin.

2. The cocrystal of claim 1 wherein the coformer is vanillic acid.

3. The cocrystal of claim 2 , wherein the molar ratio of progesterone to vanillic acid in the cocrystal is 1:1.

4. The cocrystal of claim 1 , wherein the coformer is benzoic acid.

5. The cocrystal of claim 4 , wherein the molar ratio of progesterone to benzoic acid is 2:1.

6. The cocrystal of claim 5 , wherein the cocrystal is a hemihydrate.

7. The cocrystal of claim 1 , wherein the coformer is salicylic acid.

8. The cocrystal of claim 7 , wherein the molar ratio of progesterone to salicylic acid is 1:1.

9. The cocrystal of claim 7 , wherein the molar ratio of progesterone to salicylic acid is 2:1.

10. The cocrystal of claim 1 , wherein the coformer is vanillin.

11. The cocrystal of claim 10 , wherein the molar ratio of progesterone to vanillin is 2:1.

12. The cocrystal of claim 1 , wherein the coformer is cinnamic acid.

13. The cocrystal of claim 12 , wherein the coformer is trans-cinnamic acid.

14. A pharmaceutical composition comprising a cocrystal of claim 1 and at least one pharmaceutically acceptable carrier.

15. The pharmaceutical composition of claim 14 , wherein the coformer is vanillic acid.

16. The pharmaceutical composition of claim 14 , wherein the coformer is benzoic acid.

17. The pharmaceutical composition of claim 14 , wherein the coformer is salicylic acid.

18. The pharmaceutical composition of claim 14 , wherein the coformer is vanillin.

19. The pharmaceutical composition of claim 14 , wherein the coformer is cinnamic acid.

20. A method of supplementing progesterone in women, said method comprising:

administering to a female subject in need thereof a pharmaceutical composition of claim 14 .

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2025
From: CURIA INDIANA, LLC
To: CURIA GLOBAL, INC.
Reel/Frame 073047/0677 →
CHANGE OF NAME Recorded May 20, 2025
From: AMRI SSCI, LLC
To: CURIA INDIANA, LLC
Reel/Frame 071298/0518 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON SEPTEMBER 1, 2017, AT REEL/FRAME 043746/0621 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0279 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON MARCH 16, 2023, AT REEL/FRAME 063008/0046 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0241 →
SECURITY INTEREST Recorded Mar 16, 2023
From: CURIA INDIANA, LLC (F/K/A AMRI SSCI, LLC)
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 063008/0185 →
SECURITY INTEREST Recorded Mar 16, 2023
From: CURIA INDIANA, LLC (F/K/A AMRI SSCI, LLC)
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 063008/0046 →
SECURITY INTEREST Recorded Sep 6, 2021
From: CURIA GLOBAL, INC. (FKA ALBANY MOLECULAR RESEARCH, INC.); CURIA MASSACHUSETTS, INC. (FKA AMRI BURLINGTON, INC.); CURIA WISCONSIN, INC. (FKA CEDARBURG PHARMACEUTICALS, INC.); CURIA INDIANA, LLC (FKA AMRI SSCI, LLC); CURIA NEW MEXICO, LLC (FKA OSO BIOPHARMACEUTICALS MANUFACTURING, LLC); CURIA IP HOLDINGS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 057423/0665 →
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
Reel/Frame 054252/0687 →
FIRST LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC-BY ITS SOLE MEMBER: ALO ACQUISITION LLC
To: BARCLAYS BANK, PLC AS COLLATERAL AGENT
Reel/Frame 043746/0621 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING LLC-BY ITS SOLE MEMBER:ALO ACQUISITION LLC
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 043746/0657 →
Continuity (3)
Continuation 14017397 · Sep 4, 2013
Provisional Application 61696899 · Sep 5, 2012
Related Publication 20170101433A1 · Apr 13, 2017